ArticleCNS neuroscience & therapeutics2019
Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.
Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Peripheral Blood Leukocyte Ratios as Novel Biomarkers in Brain Glioma: A Comprehensive Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2026Pooled it
- Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Expression of CD44 and the survival in glioma: a meta-analysis.Bioscience reports · 2020Pooled it
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Preoperative peripheral blood routine indicators as predictors of prognosis and diagnosis in glioma under the 2021 World Health Organization classification.Oncology letters · 2025Article
- Podoplanin expression is associated with local inflammation and survival in glioma.Scientific reports · 2025Article
- Peripheral blood-derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients.Brain pathology (Zurich, Switzerland) · 2025Article
- The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification).BMC cancer · 2023Article
- Characterization of tumor-associated reactive astrocytes in gliomas by single-cell and bulk tumor sequencing.Frontiers in neurology · 2023Article
- Predictive Value of Blood Markers in Nonfunctional Pituitary Adenomas using Artificial Neural Network.Advanced biomedical research · 2023Article
- Pre-surgery immune profiles of adult glioma patients.Journal of neuro-oncology · 2022Article
- A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2021Article
- Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.Oncogene · 2021Review
- Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A bi-center study.CNS neuroscience & therapeutics · 2021Article
- Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.Medical sciences (Basel, Switzerland) · 2021Article
- Comprehensive Analysis of Inflammatory Response-Related Genes, and Prognosis and Immune Infiltration in Patients With Low-Grade Glioma.Frontiers in pharmacology · 2021Article
- Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma.EXCLI journal · 2021Article
- The importance of the neutrophil-to-lymphocyte ratio in the prognosis of glioma and its subtypes.CNS neuroscience & therapeutics · 2020Article
- Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II-IV Glioma Recurrence.Cancer management and research · 2020Article
- Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.CNS neuroscience & therapeutics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the relationship between tumor characteristics and the preoperative counts of immune cells in peripheral blood test in glioma patients.
methodsWe included 260 WHO grades II-IV patients who had preoperative peripheral blood test result from Sanbo hospital as training set. The 66 patients from Tiantan hospital was obtained for validation. RNA sequencing data from CGGA and TCGA datasets were used to evaluate the features of neutrophil subtype and lymphocyte subtype in glioma.
resultsWe revealed that the count of preoperative lymphocytes, eosinophils and neutrophils were associated with glioma grades. Neutrophil-to-lymphocyte ratio (NLR) <3.2 was associated with better prognosis, whereas increased NLR was strongly corresponding with a poor prognosis. Lymphocyte type glioma patients demonstrated a positive correlation with isocitrate dehydrogenase (IDH) mutation and lower grade. IDH mutant glioma contained a higher proportion of tumor-infiltrating lymphocytes than IDH wild-type glioma. The immune subtype (neutrophil subtype and lymphocyte subtype) was an independent prognostic factor in glioma.
conclusionOur data demonstrated that NLR was an important prognostic factor in glioma. We classified that the immune subtype of glioma may contribute to a better understanding of disease pathogenesis and lead to the identification of new therapeutic targets for glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.